Skip to main content
. 2020 Mar 9;180(5):718–726. doi: 10.1001/jamainternmed.2020.0193

Figure 3. Cumulative Incidence of End-stage Kidney Disease (ESKD) Accounting for the Competing Risk of Death by Angiotensin-Converting Enzyme Inhibitor (ACE-I) and Angiotensin II Receptor Blocker (ARB) Discontinuation Status.

Figure 3.

eGFR indicates estimated glomerular filtration rate.